Millennium, Xoma inflammation deal

The companies will develop MLNM's CAB-2 and LDP-01 for certain vascular inflammation

Read the full 120 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE